On December 30th, Mapaxixavir Capsules (trade name: Yilikang®), a Class 1 innovative anti-influenza drug under Health-One Pharmaceutical Group, was launched online on the JD Health platform. This is an innovative oral treatment for influenza. Users can easily inquire and purchase it by searching for "Yilikang" on the JD APP, and quickly obtain cutting-edge antiviral treatment options.
Influenza is an acute respiratory infectious disease caused by the influenza virus, and its harm is far greater than that of the common cold. Information released by the National Health Commission shows that influenza activity is currently at a high level nationwide. Influenza is highly contagious, has a rapid onset, and can cause symptoms such as high fever, body aches, and fatigue. It can also lead to serious complications such as pneumonia and myocarditis, posing a significant threat to the health of the entire population, especially children, the elderly, and patients with chronic diseases. Timely and effective antiviral treatment is key to blocking virus transmission, shortening the course of the disease, and reducing the risk of severe illness.
As a novel anti-influenza drug in China, mapasixavir capsules offer a new option for influenza treatment due to their innovative mechanism of action and convenient dosing regimen. As a cap-dependent endonuclease inhibitor, mapasixavir precisely inhibits the PA endonuclease activity essential for early influenza virus replication, effectively "shutting off" viral replication at its source and preventing large-scale viral proliferation in the body. Yilikang® exhibits broad-spectrum antiviral activity against both currently prevalent influenza A and B viruses, rapidly relieving influenza symptoms such as fever, headache, and muscle aches. Its single oral administration is not only convenient but also helps reduce the risk of ineffective treatment or drug resistance due to missed doses, providing patients with a more patient-friendly and reassuring treatment experience.
Health-One Pharmaceutical Group is an innovative, research-driven, and comprehensive pharmaceutical group that consistently adheres to technological innovation as its foundation, focuses on unmet clinical needs, and implements an innovative development strategy. Currently, Health-One has developed over 20 Class 1 innovative drugs, more than 10 of which have entered Phase II or later critical stages, covering multiple high-barrier-to-entry areas such as respiratory, analgesia, and psychiatric fields.
This online launch of Yilikang® marks the beginning of a deeper collaboration between JD Health and Health Yuan. JD Health will leverage its strengths as the "first stop for the online launch of new and special drugs," relying on its omni-channel marketing resources and efficient supply chain, to help Yilikang® quickly reach more patients nationwide. Simultaneously, the professional medication consultation services provided by JD Health will safeguard patients' safe medication use.
In the future, Health Yuan and JD Health will focus on the full-cycle needs of influenza prevention and control, and carry out in-depth cooperation in areas such as improving drug accessibility, patient education, and influenza early warning, to jointly build an integrated health service ecosystem of "prevention-treatment-rehabilitation" and provide more comprehensive and considerate protection for public health.
https://bydrug.pharmcube.com/news/detail/bce10115da870882a0d4d7b23df54c25